<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20231111230923&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20231111230923&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sun, 12 Nov 2023 04:09:26 +0000</lastbuilddate>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>A Complex Anterior Mediastinal Mass in a Young Adult</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067585. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950914</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067585>10.1161/CIRCULATIONAHA.123.067585</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950914</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Giselle Alexandra Suero-Abreu</dc:creator>
<dc:creator>Lily Sung</dc:creator>
<dc:creator>Anushri Parakh</dc:creator>
<dc:creator>Brian Ghoshhajra</dc:creator>
<dc:creator>Tomas G Neilan</dc:creator>
<dc:creator>Doreen DeFaria Yeh</dc:creator>
<dc:creator>Yin P Hung</dc:creator>
<dc:creator>Danielle B Cameron</dc:creator>
<dc:creator>Jordan P Bloom</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Complex Anterior Mediastinal Mass in a Young Adult</dc:title>
<dc:identifier>pmid:37950914</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067585</dc:identifier>
</item>
<item>
<title>Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>Background: Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. Methods: In this prospective, randomized, open-label, blinded endpoint trial, in a single...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067597. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. <b>Methods:</b> In this prospective, randomized, open-label, blinded endpoint trial, in a single UK hospital, 220 women were randomly assigned 1:1 to self-monitoring with research physician-optimized antihypertensive titration, or usual postnatal care from primary care physician and midwife. Participants were aged 18 years or over, with pre-eclampsia or gestational hypertension, requiring antihypertensives on hospital discharge postnatally. Pre-specified secondary cardiac imaging outcomes were recorded by echocardiography around delivery, and again at blood pressure primary outcome assessment, around nine months postpartum, when cardiovascular magnetic resonance was also performed. <b>Results:</b> 187 women (101 intervention; 86 usual care) underwent echocardiography at baseline and follow up, at a mean 258+/-14.6 days postpartum, of which 174 (93 intervention; 81 usual care) also had cardiovascular magnetic resonance at follow up. Relative wall thickness by echocardiography was 0.06 (95% CI0.07 to 0.05, P=&lt;0.001) lower in the intervention group between baseline and follow up, and cardiovascular magnetic resonance at follow up demonstrated a lower left ventricular mass (-6.37g/m<sup>2</sup> (95% CI -7.99 to -4.74, P&lt;0.001), end diastolic volume (-3.87ml/m<sup>2</sup>, 95% CI -6.77 to -0.98, P=0.009) and end systolic volume (-3.25ml/m<sup>2</sup>, 95% CI 4.87 to -1.63, P &lt;0.001) and higher left and right ventricular ejection fraction by 2.6% (95% CI 1.3 to 3.9, P&lt;0.001) and 2.8% (95% CI 1.4 to 4.1, P&lt;0.001) respectively. Echocardiography assessed left ventricular diastolic function demonstrated a mean difference in average E/E' of 0.52 (95% CI -0.97 to -0.07, P=0.024), and a reduction in left atrial volumes of -4.33ml/m<sup>2</sup> (95% CI -5.52 to -3.21, P=&lt;0.001) between baseline and follow up, when adjusted for baseline differences in measures. <b>Conclusions:</b> Short-term postnatal optimization of blood pressure control following hypertensive pregnancy, through self-monitoring and physician-guided antihypertensive titration, associates with long term changes in cardiovascular structure and function, in a pattern associated with more favorable cardiovascular outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950907</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067597>10.1161/CIRCULATIONAHA.123.067597</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950907</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jamie Kitt</dc:creator>
<dc:creator>Samuel Krasner</dc:creator>
<dc:creator>Logan Barr</dc:creator>
<dc:creator>Annabelle Frost</dc:creator>
<dc:creator>Katherine Tucker</dc:creator>
<dc:creator>Paul A Bateman</dc:creator>
<dc:creator>Katie Suriano</dc:creator>
<dc:creator>Yvonne Kenworthy</dc:creator>
<dc:creator>Winok Lapidaire</dc:creator>
<dc:creator>Miriam Lacharie</dc:creator>
<dc:creator>Rebecca Mills</dc:creator>
<dc:creator>Cristian Roman</dc:creator>
<dc:creator>Lucy Mackillop</dc:creator>
<dc:creator>Alexandra Cairns</dc:creator>
<dc:creator>Christina Aye</dc:creator>
<dc:creator>Vanessa Ferreira</dc:creator>
<dc:creator>Stefan Piechnik</dc:creator>
<dc:creator>Elena Lukaschuk</dc:creator>
<dc:creator>Basky Thilaganathan</dc:creator>
<dc:creator>Lucy C Chappell</dc:creator>
<dc:creator>Adam J Lewandowski</dc:creator>
<dc:creator>Richard J McManus</dc:creator>
<dc:creator>Paul Leeson</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</dc:title>
<dc:identifier>pmid:37950907</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067597</dc:identifier>
</item>
<item>
<title>Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>Background: The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). Methods: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk for developing HF were identified using 1-step screening strategies: risk score...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). <b>Methods:</b> Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk for developing HF were identified using 1-step screening strategies: risk score (WATCH-DM≥12); N-terminal pro-B-type natriuretic peptide (NT-proBNP;≥125 pg/mL); high-sensitivity cardiac troponin (hs-cTnT ≥14 ng/L, hs-cTnI≥31 ng/L); echocardiography-based diabetic cardiomyopathy (echo-DbCM; LA enlargement, LV hypertrophy, or diastolic dysfunction). High-risk participants were also identified using 2-step screening strategies with a second test to additionally identify residual risk among those deemed low-risk by the first test: WATCH-DM/NT-proBNP, NT-proBNP/hs-cTn, NT-proBNP/echo-DbCM. Across screening strategies, the proportion of HF events identified, 5-year number needed to treat (NNT<sup>5</sup>) and number needed to screen (NNS<sup>5</sup>) to prevent 1 HF event with an SGLT2i among high-risk participants, and cost of screening were estimated. <b>Results:</b> The initial study cohort included 6,293 participants (48.2% women), of which 77.7% without prevalent ASCVD were evaluated with different HF screening strategies. At 5-year follow-up, 6.2% of participants without ASCVD developed incident HF. The NNT<sup>5</sup> to prevent 1 HF event with an SGLT2i among participants without ASCVD was 43 (95%CI, 29-72). In the cohort without ASCVD, high-risk participants identified using 1-step screening strategies had low NNT<sup>5</sup> (22 for NT-proBNP to 37 for echo-DbCM). However, a substantial proportion of HF events occurred among participants identified as low-risk using 1-step screening approaches (29% for echo-DbCM to 47% for hs-cTn). 2-step screening strategies captured most HF events (75-89%) in the high-risk subgroup with a comparable NNT<sup>5</sup> as the 1-step screening approaches (30-32). The NNS<sup>5</sup> to prevent 1 HF event was similar across 2-step screening strategies (45-61). However, the number of tests and associated costs were lowest for WATCH-DM/NT-proBNP ($1,061) compared with other 2-step screening strategies (NT-proBNP/hs-cTn: $2,894; NT-proBNP/echo-DbCM: $16,358). <b>Conclusions:</b> Selective NT-proBNP testing based on the WATCH-DM score efficiently identified a high-risk primary prevention population with diabetes expected to derive marked absolute benefits from SGLT2i to prevent HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950893</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067530>10.1161/CIRCULATIONAHA.123.067530</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950893</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kershaw V Patel</dc:creator>
<dc:creator>Matthew W Segar</dc:creator>
<dc:creator>David C Klonoff</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Muhammad Shariq Usman</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Andrew P DeFilippis</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Stephan J L Bakker</dc:creator>
<dc:creator>B Daan Westenbrink</dc:creator>
<dc:creator>Robin P F Dullaart</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis</dc:title>
<dc:identifier>pmid:37950893</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067530</dc:identifier>
</item>
<item>
<title>Device-measured physical activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) consortium</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Compositional data analyses revealed a distinct hierarchy of behaviours. Moderate-vigorous physical activity demonstrated the strongest, most time-efficient protective associations with cardiometabolic outcomes. Theoretical benefits from reallocating SB into sleep, standing, or LIPA required substantial changes in daily activity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 10:ehad717. doi: 10.1093/eurheartj/ehad717. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Physical inactivity, sedentary behaviour (SB), and inadequate sleep are key behavioural risk factors of cardiometabolic diseases. Each behaviour is mainly considered in isolation, despite clear behavioural and biological interdependencies. The aim of this study was to investigate associations of five-part movement compositions with adiposity and cardiometabolic biomarkers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cross-sectional data from six studies (n = 15 253 participants; five countries) from the Prospective Physical Activity, Sitting and Sleep consortium were analysed. Device-measured time spent in sleep, SB, standing, light-intensity physical activity (LIPA), and moderate-vigorous physical activity (MVPA) made up the composition. Outcomes included body mass index (BMI), waist circumference, HDL cholesterol, total:HDL cholesterol ratio, triglycerides, and glycated haemoglobin (HbA1c). Compositional linear regression examined associations between compositions and outcomes, including modelling time reallocation between behaviours.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The average daily composition of the sample (age: 53.7 ± 9.7 years; 54.7% female) was 7.7 h sleeping, 10.4 h sedentary, 3.1 h standing, 1.5 h LIPA, and 1.3 h MVPA. A greater MVPA proportion and smaller SB proportion were associated with better outcomes. Reallocating time from SB, standing, LIPA, or sleep into MVPA resulted in better scores across all outcomes. For example, replacing 30 min of SB, sleep, standing, or LIPA with MVPA was associated with -0.63 (95% confidence interval -0.48, -0.79), -0.43 (-0.25, -0.59), -0.40 (-0.25, -0.56), and -0.15 (0.05, -0.34) kg/m2 lower BMI, respectively. Greater relative standing time was beneficial, whereas sleep had a detrimental association when replacing LIPA/MVPA and positive association when replacing SB. The minimal displacement of any behaviour into MVPA for improved cardiometabolic health ranged from 3.8 (HbA1c) to 12.7 (triglycerides) min/day.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compositional data analyses revealed a distinct hierarchy of behaviours. Moderate-vigorous physical activity demonstrated the strongest, most time-efficient protective associations with cardiometabolic outcomes. Theoretical benefits from reallocating SB into sleep, standing, or LIPA required substantial changes in daily activity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950859</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad717>10.1093/eurheartj/ehad717</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950859</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Joanna M Blodgett</dc:creator>
<dc:creator>Matthew N Ahmadi</dc:creator>
<dc:creator>Andrew J Atkin</dc:creator>
<dc:creator>Sebastien Chastin</dc:creator>
<dc:creator>Hsiu-Wen Chan</dc:creator>
<dc:creator>Kristin Suorsa</dc:creator>
<dc:creator>Esmee A Bakker</dc:creator>
<dc:creator>Pasan Hettiarcachchi</dc:creator>
<dc:creator>Peter J Johansson</dc:creator>
<dc:creator>Lauren B Sherar</dc:creator>
<dc:creator>Vegar Rangul</dc:creator>
<dc:creator>Richard M Pulsford</dc:creator>
<dc:creator>Gita Mishra</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:creator>Sari Stenholm</dc:creator>
<dc:creator>Alun D Hughes</dc:creator>
<dc:creator>Armando M Teixeira-Pinto</dc:creator>
<dc:creator>Ulf Ekelund</dc:creator>
<dc:creator>I Min Lee</dc:creator>
<dc:creator>Andreas Holtermann</dc:creator>
<dc:creator>Annemarie Koster</dc:creator>
<dc:creator>Emmanuel Stamatakis</dc:creator>
<dc:creator>Mark Hamer</dc:creator>
<dc:creator>ProPASS Collaboration</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Device-measured physical activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) consortium</dc:title>
<dc:identifier>pmid:37950859</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad717</dc:identifier>
</item>
<item>
<title>Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: The C3PO NLP model developed within 1 health care system identified HF events with good agreement relative to the gold-standard CEC in an external multicenter clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. Further study is needed to determine whether NLP will improve the efficiency of future multicenter clinical trials by identifying clinical events at scale.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 11. doi: 10.1001/jamacardio.2023.4859. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The gold standard for outcome adjudication in clinical trials is medical record review by a physician clinical events committee (CEC), which requires substantial time and expertise. Automated adjudication of medical records by natural language processing (NLP) may offer a more resource-efficient alternative but this approach has not been validated in a multicenter setting.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To externally validate the Community Care Cohort Project (C3PO) NLP model for heart failure (HF) hospitalization adjudication, which was previously developed and tested within one health care system, compared to gold-standard CEC adjudication in a multicenter clinical trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of the Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial, which compared 2 influenza vaccines in 5260 participants with cardiovascular disease at 157 sites in the US and Canada between September 2016 and January 2019. Analysis was performed from November 2022 to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Individual sites submitted medical records for each hospitalization. The central INVESTED CEC and the C3PO NLP model independently adjudicated whether the cause of hospitalization was HF using the prepared hospitalization dossier. The C3PO NLP model was fine-tuned (C3PO + INVESTED) and a de novo NLP model was trained using half the INVESTED hospitalizations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Concordance between the C3PO NLP model HF adjudication and the gold-standard INVESTED CEC adjudication was measured by raw agreement, κ, sensitivity, and specificity. The fine-tuned and de novo INVESTED NLP models were evaluated in an internal validation cohort not used for training.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4060 hospitalizations in 1973 patients (mean [SD] age, 66.4 [13.2] years; 514 [27.4%] female and 1432 [72.6%] male]), 1074 hospitalizations (26%) were adjudicated as HF by the CEC. There was good agreement between the C3PO NLP and CEC HF adjudications (raw agreement, 87% [95% CI, 86-88]; κ, 0.69 [95% CI, 0.66-0.72]). C3PO NLP model sensitivity was 94% (95% CI, 92-95) and specificity was 84% (95% CI, 83-85). The fine-tuned C3PO and de novo NLP models demonstrated agreement of 93% (95% CI, 92-94) and κ of 0.82 (95% CI, 0.77-0.86) and 0.83 (95% CI, 0.79-0.87), respectively, vs the CEC. CEC reviewer interrater reproducibility was 94% (95% CI, 93-95; κ, 0.85 [95% CI, 0.80-0.89]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The C3PO NLP model developed within 1 health care system identified HF events with good agreement relative to the gold-standard CEC in an external multicenter clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. Further study is needed to determine whether NLP will improve the efficiency of future multicenter clinical trials by identifying clinical events at scale.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950744</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4859>10.1001/jamacardio.2023.4859</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950744</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>Pulkit Singh</dc:creator>
<dc:creator>Christopher Reeder</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Pablo M Marti-Castellote</dc:creator>
<dc:creator>Emily S Lau</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:creator>Puneet Batra</dc:creator>
<dc:creator>Steven A Lubitz</dc:creator>
<dc:creator>Mahnaz Maddah</dc:creator>
<dc:creator>Anthony Philippakis</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37950744</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4859</dc:identifier>
</item>
<item>
<title>Innovation in Event Adjudication-Human vs Machine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 11. doi: 10.1001/jamacardio.2023.4900. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950739</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4900>10.1001/jamacardio.2023.4900</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950739</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Innovation in Event Adjudication-Human vs Machine</dc:title>
<dc:identifier>pmid:37950739</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4900</dc:identifier>
</item>
<item>
<title>Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>Background: Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization when compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy (CRT). We sought to compare the occurrence of sustained ventricular tachycardia or ventricular fibrillation (VT/VF) and new onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. Methods: This...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067465. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization when compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy (CRT). We sought to compare the occurrence of sustained ventricular tachycardia or ventricular fibrillation (VT/VF) and new onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. <b>Methods:</b> This International Collaborative LBBAP Study (I-CLAS) included patients with LVEF≤35% who underwent BVP or LBBAP for CRT between Jan 2018 to June 2022 at 15 centers. We performed propensity score matched (PS) analysis of LBBAP and BVP in a 1:1 ratio. We assessed the incidence of VT/VF and new-onset AF among patients with no prior history of AF. Time to sustained VT/VF and time to new-onset AF was analyzed using Cox proportional hazards survival model. <b>Results:</b> Among 1778 patients undergoing CRT (981-BVP, 797-LBBAP), PS matched 1414 patients (PS-BVP:707, PS-LBBAP:707). The occurrence of VT/VF was significantly lower with LBBAP compared with BVP (4.2% vs 9.3%;HR 0.46;95%CI 0.29-0.74;p&lt;0.001). The incidence of VT storm (>;3 episodes in 24 hours) was also significantly lower with LBBAP compared with BVP (0.8% vs 2.5%;p=0.013). Among 299 patients with CRT-pacemakers (BVP-111, LBBAP-188), VT/VF occurred in 8 patients in the BVP group vs. none in the LBBAP group (7.2% vs 0%;p&lt;0.001). In 1194 patients with no prior history of VT/VF or antiarrhythmic therapy (BVP-591, LBBAP-603), the occurrence of VT/VF was significantly lower with LBBAP compared with BVP (3.2% vs 7.3%;HR 0.46;95%CI 0.26-0.81;p=0.007). Among patients with no prior history of AF (n=890), the occurrence of new-onset AF >;30 seconds was significantly lower with LBBAP compared with BVP (2.8% vs 6.6%;HR 0.34;95%CI 0.16-0.73;p=0.008). The incidence of AF lasting >;24 hours was also significantly lower with LBBAP compared with BVP (0.7% vs 2.9%;p=0.015). <b>Conclusions:</b> LBBAP was associated with lower incidence of sustained VT/VF and new-onset AF compared with BVP. This difference remained significant after adjustment for differences in baseline characteristics between patients with BVP and LBBAP. Physiologic resynchronization by LBBAP may be associated with lower risk of arrhythmias compared with BVP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950738</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067465>10.1161/CIRCULATIONAHA.123.067465</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950738</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bengt Herweg</dc:creator>
<dc:creator>Parikshit S Sharma</dc:creator>
<dc:creator>Oscar Cano</dc:creator>
<dc:creator>Shunmuga Sundaram Ponnusamy</dc:creator>
<dc:creator>Francesco Zanon</dc:creator>
<dc:creator>Marek Jastrzebski</dc:creator>
<dc:creator>Jiangang Zou</dc:creator>
<dc:creator>Mihail G Chelu</dc:creator>
<dc:creator>Kevin Vernooy</dc:creator>
<dc:creator>Zachary I Whinnett</dc:creator>
<dc:creator>Girish M Nair</dc:creator>
<dc:creator>Manuel Molina-Lerma</dc:creator>
<dc:creator>Karol Curila</dc:creator>
<dc:creator>Dipen Zalavadia</dc:creator>
<dc:creator>Cicely Dye</dc:creator>
<dc:creator>Sharath C Vipparthy</dc:creator>
<dc:creator>Ryan Brunetti</dc:creator>
<dc:creator>Mishal Mumtaz</dc:creator>
<dc:creator>Pawel Moskal</dc:creator>
<dc:creator>Andrew M Leong</dc:creator>
<dc:creator>Antonius van Stipdonk</dc:creator>
<dc:creator>Jerin George</dc:creator>
<dc:creator>Yusuf K Qadeer</dc:creator>
<dc:creator>Jeffrey Kolominsky</dc:creator>
<dc:creator>Mehrdad Golian</dc:creator>
<dc:creator>Ramez Morcos</dc:creator>
<dc:creator>Lina Marcantoni</dc:creator>
<dc:creator>Faiz A Subzposh</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:creator>Pugazhendhi Vijayaraman</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS)</dc:title>
<dc:identifier>pmid:37950738</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067465</dc:identifier>
</item>
<item>
<title>Neutrophil counts and cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Observational and genetically determined high neutrophil counts were associated with atherosclerotic cardiovascular disease, supporting that high blood neutrophil counts is a causal risk factor for atherosclerotic cardiovascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad649. doi: 10.1093/eurheartj/ehad649. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Anti-inflammatory trials have shown considerable benefits for cardiovascular disease. High neutrophil counts, an easily accessible inflammation biomarker, are associated with atherosclerosis in experimental studies. This study aimed to investigate the associations between neutrophil counts and risk of nine cardiovascular endpoints using observational and genetic approaches.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Observational studies were conducted in the Copenhagen General Population Study (n = 101 730). Genetic studies were firstly performed using one-sample Mendelian randomization (MR) with individual-level data from the UK Biobank (n = 365 913); secondly, two-sample MR analyses were performed using summary-level data from the Blood Cell Consortium (n = 563 085). Outcomes included ischaemic heart disease, myocardial infarction, peripheral arterial disease, ischaemic cerebrovascular disease, ischaemic stroke, vascular-related dementia, vascular dementia, heart failure, and atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Observational analyses showed associations between high neutrophil counts with high risks of all outcomes. In the UK Biobank, odds ratios (95% confidence intervals) per 1-SD higher genetically predicted neutrophil counts were 1.15 (1.08, 1.21) for ischaemic heart disease, 1.22 (1.12, 1.34) for myocardial infarction, and 1.19 (1.04, 1.36) for peripheral arterial disease; similar results were observed in men and women separately. In two-sample MR, corresponding estimates were 1.14 (1.05, 1.23) for ischaemic heart disease and 1.11 (1.02, 1.20) for myocardial infarction; multiple sensitivity analyses showed consistent results. No robust associations in two-sample MR analyses were found for other types of leucocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Observational and genetically determined high neutrophil counts were associated with atherosclerotic cardiovascular disease, supporting that high blood neutrophil counts is a causal risk factor for atherosclerotic cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950632</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad649>10.1093/eurheartj/ehad649</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950632</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jiao Luo</dc:creator>
<dc:creator>Jesper Qvist Thomassen</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:creator>Anne Tybjærg-Hansen</dc:creator>
<dc:creator>Ruth Frikke-Schmidt</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Neutrophil counts and cardiovascular disease</dc:title>
<dc:identifier>pmid:37950632</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad649</dc:identifier>
</item>
<item>
<title>Timing treatment for tricuspid regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad768. doi: 10.1093/eurheartj/ehad768. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950518</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad768>10.1093/eurheartj/ehad768</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950518</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kush P Patel</dc:creator>
<dc:creator>Andreas Baumbach</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Timing treatment for tricuspid regurgitation</dc:title>
<dc:identifier>pmid:37950518</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad768</dc:identifier>
</item>
<item>
<title>A fish bone wandering in the body</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950498/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad754. doi: 10.1093/eurheartj/ehad754. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950498/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950498</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad754>10.1093/eurheartj/ehad754</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950498</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yiyuan Li</dc:creator>
<dc:creator>Qiang Guo</dc:creator>
<dc:creator>Bin Huang</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A fish bone wandering in the body</dc:title>
<dc:identifier>pmid:37950498</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad754</dc:identifier>
</item>
<item>
<title>Interplay between coronary bridging and high shear stress in the emergence of coronary vasospasm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950497/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad762. doi: 10.1093/eurheartj/ehad762. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950497/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950497</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad762>10.1093/eurheartj/ehad762</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950497</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Tijn P J Jansen</dc:creator>
<dc:creator>Jolanda J Wentzel</dc:creator>
<dc:creator>Peter Damman</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Interplay between coronary bridging and high shear stress in the emergence of coronary vasospasm</dc:title>
<dc:identifier>pmid:37950497</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad762</dc:identifier>
</item>
<item>
<title>A rare septal diverticulum found in a dilated cardiomyopathy: guilty or innocent?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37950453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad759. doi: 10.1093/eurheartj/ehad759. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37950453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37950453</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad759>10.1093/eurheartj/ehad759</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37950453</guid>
<pubDate>Sat, 11 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ting Liu</dc:creator>
<dc:creator>Lokyi Tsang</dc:creator>
<dc:creator>Qing Zhang</dc:creator>
<dc:date>2023-11-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A rare septal diverticulum found in a dilated cardiomyopathy: guilty or innocent?</dc:title>
<dc:identifier>pmid:37950453</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad759</dc:identifier>
</item>
<item>
<title>Long COVID and its cardiovascular implications: a call to action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949826/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad723. doi: 10.1093/eurheartj/ehad723. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949826/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949826</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad723>10.1093/eurheartj/ehad723</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949826</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ziyad Al-Aly</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long COVID and its cardiovascular implications: a call to action</dc:title>
<dc:identifier>pmid:37949826</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad723</dc:identifier>
</item>
<item>
<title>Different techniques of venous access for CIEDs: advantages and disadvantages</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad749. doi: 10.1093/eurheartj/ehad749. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949825</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad749>10.1093/eurheartj/ehad749</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949825</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Michele Brignole</dc:creator>
<dc:creator>Jean-Claude Deharo</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Different techniques of venous access for CIEDs: advantages and disadvantages</dc:title>
<dc:identifier>pmid:37949825</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad749</dc:identifier>
</item>
<item>
<title>Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949824/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad742. doi: 10.1093/eurheartj/ehad742. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949824/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949824</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad742>10.1093/eurheartj/ehad742</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949824</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Neusa Jessen</dc:creator>
<dc:creator>Ana Olga Mocumbi</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent</dc:title>
<dc:identifier>pmid:37949824</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad742</dc:identifier>
</item>
<item>
<title>Bioelectronics for neurocardiology: diagnosis and therapeutics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949823/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad624. doi: 10.1093/eurheartj/ehad624. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949823/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949823</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad624>10.1093/eurheartj/ehad624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949823</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>David J Paterson</dc:creator>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:creator>Bioelectronics for Neurocardiology Consortium</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bioelectronics for neurocardiology: diagnosis and therapeutics</dc:title>
<dc:identifier>pmid:37949823</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad624</dc:identifier>
</item>
<item>
<title>Dysphagia caused by a double aortic arch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949822/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad752. doi: 10.1093/eurheartj/ehad752. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949822/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949822</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad752>10.1093/eurheartj/ehad752</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949822</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Paul Le Corre</dc:creator>
<dc:creator>Arshid Azarine</dc:creator>
<dc:creator>Virgile Chevance</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dysphagia caused by a double aortic arch</dc:title>
<dc:identifier>pmid:37949822</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad752</dc:identifier>
</item>
<item>
<title>Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949821/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad750. doi: 10.1093/eurheartj/ehad750. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949821/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949821</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad750>10.1093/eurheartj/ehad750</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949821</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Leonhard Wert</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Evgenij V Potapov</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach</dc:title>
<dc:identifier>pmid:37949821</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad750</dc:identifier>
</item>
<item>
<title>More on aldosterone biosynthesis inhibition and resistant hypertension: a Phase-2 study with lorundrostat</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 9:ehad756. doi: 10.1093/eurheartj/ehad756. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949819</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad756>10.1093/eurheartj/ehad756</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949819</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Massimo Volpe</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>More on aldosterone biosynthesis inhibition and resistant hypertension: a Phase-2 study with lorundrostat</dc:title>
<dc:identifier>pmid:37949819</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad756</dc:identifier>
</item>
<item>
<title>Reconstruction of a fatty acid synthesis cycle from acyl carrier protein and cofactor structural snapshots</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949058/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>Fatty acids (FAs) play a central metabolic role in living cells as constituents of membranes, cellular energy reserves, and second messenger precursors. A 2.6 MDa FA synthase (FAS), where the enzymatic reactions and structures are known, is responsible for FA biosynthesis in yeast. Essential in the yeast FAS catalytic cycle is the acyl carrier protein (ACP) that actively shuttles substrates, biosynthetic intermediates, and products from one active site to another. We resolve the S. cerevisiae...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 9;186(23):5054-5067.e16. doi: 10.1016/j.cell.2023.10.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Fatty acids (FAs) play a central metabolic role in living cells as constituents of membranes, cellular energy reserves, and second messenger precursors. A 2.6 MDa FA synthase (FAS), where the enzymatic reactions and structures are known, is responsible for FA biosynthesis in yeast. Essential in the yeast FAS catalytic cycle is the acyl carrier protein (ACP) that actively shuttles substrates, biosynthetic intermediates, and products from one active site to another. We resolve the S. cerevisiae FAS structure at 1.9 Å, elucidating cofactors and water networks involved in their recognition. Structural snapshots of ACP domains bound to various enzymatic domains allow the reconstruction of a full yeast FA biosynthesis cycle. The structural information suggests that each FAS functional unit could accommodate exogenous proteins to incorporate various enzymatic activities, and we show proof-of-concept experiments where ectopic proteins are used to modulate FAS product profiles.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949058/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949058</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.009>10.1016/j.cell.2023.10.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949058</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kashish Singh</dc:creator>
<dc:creator>Georg Bunzel</dc:creator>
<dc:creator>Benjamin Graf</dc:creator>
<dc:creator>Ka Man Yip</dc:creator>
<dc:creator>Meina Neumann-Schaal</dc:creator>
<dc:creator>Holger Stark</dc:creator>
<dc:creator>Ashwin Chari</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Reconstruction of a fatty acid synthesis cycle from acyl carrier protein and cofactor structural snapshots</dc:title>
<dc:identifier>pmid:37949058</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.009</dc:identifier>
</item>
<item>
<title>Proteostasis governs differential temperature sensitivity across embryonic cell types</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37949057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231111230923&amp;v=2.17.9.post6+86293ac
      <description>Embryonic development is remarkably robust, but temperature stress can degrade its ability to generate animals with invariant anatomy. Phenotypes associated with environmental stress suggest that some cell types are more sensitive to stress than others, but the basis of this sensitivity is unknown. Here, we characterize hundreds of individual zebrafish embryos under temperature stress using whole-animal single-cell RNA sequencing (RNA-seq) to identify cell types and molecular programs driving...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 9;186(23):5015-5027.e12. doi: 10.1016/j.cell.2023.10.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Embryonic development is remarkably robust, but temperature stress can degrade its ability to generate animals with invariant anatomy. Phenotypes associated with environmental stress suggest that some cell types are more sensitive to stress than others, but the basis of this sensitivity is unknown. Here, we characterize hundreds of individual zebrafish embryos under temperature stress using whole-animal single-cell RNA sequencing (RNA-seq) to identify cell types and molecular programs driving phenotypic variability. We find that temperature perturbs the normal proportions and gene expression programs of numerous cell types and also introduces asynchrony in developmental timing. The notochord is particularly sensitive to temperature, which we map to a specialized cell type: sheath cells. These cells accumulate misfolded protein at elevated temperature, leading to a cascading structural failure of the notochord and anatomic defects. Our study demonstrates that whole-animal single-cell RNA-seq can identify mechanisms for developmental robustness and pinpoint cell types that constitute key failure points.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37949057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231111230923&v=2.17.9.post6+86293ac">37949057</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.013>10.1016/j.cell.2023.10.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37949057</guid>
<pubDate>Fri, 10 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Michael W Dorrity</dc:creator>
<dc:creator>Lauren M Saunders</dc:creator>
<dc:creator>Madeleine Duran</dc:creator>
<dc:creator>Sanjay R Srivatsan</dc:creator>
<dc:creator>Eliza Barkan</dc:creator>
<dc:creator>Dana L Jackson</dc:creator>
<dc:creator>Sydney M Sattler</dc:creator>
<dc:creator>Brent Ewing</dc:creator>
<dc:creator>Christine Queitsch</dc:creator>
<dc:creator>Jay Shendure</dc:creator>
<dc:creator>David W Raible</dc:creator>
<dc:creator>David Kimelman</dc:creator>
<dc:creator>Cole Trapnell</dc:creator>
<dc:date>2023-11-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Proteostasis governs differential temperature sensitivity across embryonic cell types</dc:title>
<dc:identifier>pmid:37949057</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.013</dc:identifier>
</item>





























</channel>
</rss>